<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797848</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-047</org_study_id>
    <nct_id>NCT01797848</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients</brief_title>
  <acronym>COMMAND-Asia</acronym>
  <official_title>A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 24 week treatment with the Daclatasvir
      (DCV) in combination with Pegylated-interferon alfa 2a (pegIFNα-2a) and Ribavirin (RBV) is
      safe and demonstrates rate of Sustained Virologic Response at follow up week 24 (SVR24)
      (defined as undetectable HCV RNA at post-treatment Week 24) that are non-inferior to 48 weeks
      of the dual combination therapy of pegIFNα-2a/RBV in a majority of study subjects
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Genotype 1 subjects with SVR24, defined as HCV RNA &lt; Limit of quantification (LOQ) at follow-up Week 24 for each cohort</measure>
    <time_frame>Week 24 post treatment follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Genotype (GT) 4 subjects with SVR24</measure>
    <time_frame>Week 24 post treatment follow up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of GT 1 &amp; 4 subjects who achieve HCV RNA &lt; LOQ or undetectable</measure>
    <time_frame>Week 24 post treatment follow up visit and Week 48 post treatment follow up visit for subjects who achieve Virologic response [VR] (4&amp;12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Serious Adverse Events (SAEs)/discontinuations due to Adverse Events (AEs)</measure>
    <time_frame>Up to 48 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations due to Adverse Events (AEs)</measure>
    <time_frame>Up to 48 weeks plus 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Sustained Virologic Response at follow up week 12 (SVR12) or SVR24 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</measure>
    <time_frame>Up to 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>pegIFNα 2a + Ribavirin + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks
Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks
Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pegIFNα 2a + Ribavirin + Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response
Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response
Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa 2a</intervention_name>
    <arm_group_label>pegIFNα 2a + Ribavirin + Placebo</arm_group_label>
    <arm_group_label>pegIFNα 2a + Ribavirin + Daclatasvir</arm_group_label>
    <other_name>Pegasys®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>pegIFNα 2a + Ribavirin + Placebo</arm_group_label>
    <arm_group_label>pegIFNα 2a + Ribavirin + Daclatasvir</arm_group_label>
    <other_name>Copegus® (Taiwan, Korea and Singapore)</other_name>
    <other_name>Wei Lining (China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Daclatasvir</intervention_name>
    <arm_group_label>pegIFNα 2a + Ribavirin + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>pegIFNα 2a + Ribavirin + Daclatasvir</arm_group_label>
    <other_name>BMS-790052-05</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients chronically infected with Hepatitis C virus (HCV) GT 1 or 4

          -  HCV RNA viral load ≥ 10,000 IU/mL

          -  Naïve to prior treatment with any interferon formulation, Ribavirin (RBV) or HCV
             direct antiviral agent

          -  Patients with compensated cirrhosis are permitted

        Exclusion Criteria:

          -  Infected with HCV other than GT 1 or 4

          -  Evidence of decompensated liver disease

          -  Documented or suspected Hepatocellular carcinoma (HCC) as evidenced by previously
             obtained imaging studies or liver biopsy

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV

          -  History of chronic Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)

          -  Current or know history of cancer (except in situ carcinoma of cervix or adequately
             treated basal or squamous cell carcinoma of the skin) within 5 years prior to
             enrollment

          -  Laboratory values:

               1. Hemoglobin &lt; 12 g/dL (females) or &lt; 13 g/dL (males)

               2. Platelets &lt; 90 x 1000000000 cells/L

               3. Absolute neutrophil count (ANC) &lt; 1.5 × 1000000000 cells/L

               4. Total bilirubin ≥ 34 µmol/L (unless due to Gilbert's disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

